![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 02, 2014 4:26:02 PM
I think most are here for "K" as it offers incredible opportunities for use considering wild/mutant P53 is implicated in so many cancer types. It's exciting to see we have not had serious safety setbacks thus far and are now in the range where true therapeutic utility is anticipated. Couple that with the suggestive benefit to a small sample set of patients at low doses (restaging of patients) definitely gets us excited since the results were with advanced 4th stage patients. Intuitively repair of P53 might best be achieved by use of the drug earlier in the disease process (stage 1/2) so there is less of a tumor burden and before the patients immune systems are not as compromised as those who have gone thru several types or rounds of debilitating chemotherapy. I think this might ultimately be the best use for "K" however that question will require further "targeted" trials down the road. Consider that tamoxifen, a prophylactic use drug during it's heyday was about a 600 million per year advocated for just specific types of breast cancer patients. P53 is implicated in multiple (50%?) types of cancers, thus the potential applications are staggering. The fact that Cellceutix also has "B" and "P" in the pipeline is what sets Cellceutix apart. Those that are patient will be rewarded in my opinion, it will take multiple years to fully see the potential but the potential is so mind boggling assigning a future value is almost impossible. Saturday afternoon ramblings......
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM